Approval granted by Anvisa for Mounjaro, a new treatment for obesity and overweight: learn its mechanism and price details
🚨 Boom! Mounjaro Greenlit for Obesity Treatment in Brazil
Got some weighty news for you: Mounjaro, that sweet diabetes-taming drug, can now be your ticket to a trimmer waistline! That's right, folks, Brazil's health regulator, Anvisa, has given Mounjaro the thumbs-up for obesity treatment as of Monday, 9th. And guess what? Until now, prescribing Mounjaro for obesity was kinda like playing off-label Russian roulette - risky, man!
Now, if you're rockin' a body mass index (BMI) of 30 or higher (obesity's dark and twisty definition), or you got a BMI of 27 or more and some associated health issues, like high blood pressure, high cholesterol, or prediabetes, Mounjaro's got your back!
This marks a whole new ball game for obesity treatment in Brazil. Luiz André Magno, Senior Medical Director of Eli Lilly Brazil, spilled the beans in an interview: Mounjaro's obesity approval is a ball of wax due to studies submission stages - first, diabetes focused, then, obesity investigation phase 3. With the analysis wrapped up, Anvisa gave the green light to this new indication!
Dr. Fábio Trujilho, head honcho of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso), is stoked about Mounjaro's new role against obesity: fewer off-label shenanigans means hospitals and clinics might be able to cover at least some of that treatment cost for you.
How Mounjaro kicks ass
Mounjaro's active ingredient, tirzepatide, is a week-long injectable badass that mimics the action of two tummies hormones: GLP-1 and GIP (gastric inhibitory peptide). Unlike Ozempic and Wegovy, both from Novo Nordisk, based on semaglutide and jamming only on GLP-1, Mounjaro is a dual agonist with an enhanced action.
It works similar to semaglutide, regulating blood sugar levels and promoting appetite suppression. By activating both hormones at once, Mounjaro brings the heat, showing superiority over Ozempic in treating type 2 diabetes and weight loss.
In Eli Lilly's studies, tirzepatide resulted in a whopping 20.2% reduction in body weight after 72 weeks (1.5 years), while semaglutide yielded a more modest 13.7% reduction. The average weight loss was 22.8 kg in the Mounjaro crowd and 15 kg for those treated with Wegovy.
Abdominal circumference reduction stats were also on point: tirzepatide promoted an average 18.4 cm loss, while semaglutide managed 13 cm.
Dosage and Side Effects
Tirzepatide should begin its crusade at the 2.5 mg dosage and then climb through 5 mg, 7.5 mg, 10 mg, 12.5 mg, all the way to 15 mg. Always let your doctor handle the prescription and be aware of possible side effects such as hypoglycemia, queasy stomach, and gastrointestinal distress.
How Much Cash Does it Cost?
Mounjaro emerged in Brazil with two pricing options. Through Eli Lilly's loyal program, Lilly Melhor Para Você, you can snag lower prices - enroll for free using this link: [www.lillymelhorparavoce.com.br/#beneficios].
Outside the program, Mounjaro's prices will vary by state (thanks, Brazilian sales tax).
Prescription Retention
Get ready for some paperwork: In April, Anvisa mandated prescription retention for this class of meds to nip abusive use in the bud. This rule'll go into effect in June, two months post-publication in the Official Gazette.
Medications from the Mounjaro class will receive the red label, meaning they pose "an intermediate risk of adverse effects to the user and should be prescribed by the healthcare professional."
Viva la Mounjaro! 🎉🎉🎉
- Mounjaro
- Obesity Treatment Approval in Brazil
- New Chapter in Obesity Management
Estadão Conteúdo
- With the recent approval of Mounjaro for obesity treatment in Brazil, science delves into a new chapter of health-and-wellness, offering a potential solution for weight management through a weekly injectable medication called tirzepatide.
- This innovative drug, targeting obesity and its associated health issues, is a dual agonist that mimics the action of two hormones, GLP-1 and GIP, showcasing superiority over other treatments in weight loss and type 2 diabetes management.
- Despite its potential benefits, the cost of Mounjaro varies and can be reduced through Eli Lilly's loyalty program, ensuring financial accessibility for some seeking improved health and well-being.
